News

FDA Approves GoldenBiotech’s IND Application of Antroquinonol for Phase II Trial on Relapsed Acute Myeloid Leukemia (AML) May 27, 2022 Golden Biotechnology Corp. (GBC, GoldenBiotech, TPEX 4132), a leading Taiwanese bio-pharmaceutical company announces that Antroquinonol (HOCENA®), a new small molecule drug developed by Golden Biotech, has been officially notified by …

R&D Pipeline

We believe, expect and pioneer… Based on our ultimate spirit, GBC develops new drug candidates through our solid footstone and promotes health by promising and more effective medications for oncological, autoimmune, degenerative, metabolic and orphan diseases etc. We dedicate to advancing health and welfare in whole life. R&D and Clinical …

PHARMACEUTICAL

Infectious Disease COVID-19 Potential roles of Antroquinonol in COVID-19…More BREAKTHROUGHS FOR THE IDEAL MEDICINE Golden Biotechnology Corporation is a Taiwanese based leading pharmaceutical company which dedicates to discovering new compounds and developing innovative therapeutics against serious and rare diseases in hopes to improve and promote a lasting quality of life, …